Areplivir IV (favipiravir injection) / Promomed - LARVOL DELTA

UMIT-2 - Adaptive Phase IIb Platform Trial to Determine the Efficacy and Safety of Therapeutics for CCHF (clinicaltrials.gov) - P2 | N=378 | Recruiting | Sponsor: Liverpool School of Tropical Medicine | Not yet recruiting ➔ Recruiting

Enrollment open • Hematological Disorders

AGILE (Early Phase Platform Trial for COVID-19) (clinicaltrials.gov) - P1/2 | N=600 | Recruiting | Sponsor: University of Liverpool | Trial completion date: Jul 2026 ➔ Mar 2027 | Trial primary completion date: Jul 2026 ➔ Mar 2027

Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease

UMIT-1, Phase IB Trial: IV favipiravir and ribavirin for the treatment of CCHF (ESCMID Global 2026) - No abstract available

Late-breaking abstract • P1 data

Optimal Dose and Safety of Intravenous Favipiravir in Hospitalized Patients With COVID-19: A Dose-Escalating, Randomized Controlled Phase Ib Study. (PubMed, Clin Pharmacol Ther) - P1/2 | "We consider doses up to 2,400 mg b.i.d. to be safe for further evaluation."

Journal • P1 data • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

AGILE (Early Phase Platform Trial for COVID-19) (clinicaltrials.gov) - P1/2 | N=600 | Recruiting | Sponsor: University of Liverpool | Trial completion date: Oct 2026 ➔ Jul 2026 | Trial primary completion date: Oct 2026 ➔ Jul 2026

Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease

AGILE (Early Phase Platform Trial for COVID-19) (clinicaltrials.gov) - P1/2 | N=600 | Recruiting | Sponsor: University of Liverpool | Active, not recruiting ➔ Recruiting | Trial completion date: Jul 2025 ➔ Oct 2026 | Trial primary completion date: Jul 2025 ➔ Oct 2026

Enrollment open • Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease

UMIT-2 - Adaptive Phase IIb Platform Trial to Determine the Efficacy and Safety of Therapeutics for CCHF (clinicaltrials.gov) - P2 | N=378 | Not yet recruiting | Sponsor: Liverpool School of Tropical Medicine

New P2 trial • Hematological Disorders

AGILE (Early Phase Platform Trial for COVID-19) (clinicaltrials.gov) - P1/2 | N=600 | Active, not recruiting | Sponsor: University of Liverpool | Trial completion date: Apr 2024 ➔ Jul 2025 | Trial primary completion date: Dec 2023 ➔ Jul 2025

Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease

AGILE (Early Phase Platform Trial for COVID-19) (clinicaltrials.gov) - P1/2 | N=600 | Active, not recruiting | Sponsor: University of Liverpool | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Novel Coronavirus Disease

UMIT-1 Trial Favipiravir & Ribavirin for the Treatment of CCHF (clinicaltrials.gov) - P2 | N=24 | Recruiting | Sponsor: Liverpool School of Tropical Medicine | Not yet recruiting ➔ Recruiting

Enrollment open

UMIT-1 Trial Favipiravir & Ribavirin for the Treatment of CCHF (clinicaltrials.gov) - P2 | N=24 | Not yet recruiting | Sponsor: Liverpool School of Tropical Medicine

New P2 trial

Comparison of clinical and laboratory features in coronavirus disease 2019 and pediatric multisystem inflammatory syndrome patients. (PubMed, Pediatr Int) - "Longer duration of fever, diarrhea, lower thrombocyte, and higher neutrophil count can warn clinicians for diagnosis of PIMS."

Journal • Conjunctivitis • Critical care • Dermatology • Infectious Disease • Novel Coronavirus Disease • Ocular Infections • Ocular Inflammation • Ophthalmology • Pediatrics • Respiratory Diseases

First COVID-19 injectable drug registered in Russia (ANTV) - "Recently, the manufacturer Promomed Group has registered the first intravenous drug to treat COVID-19 in Russia, and the first Favipiravir-based injection in the world. The treatment drug called 'Areplivir' is expected to be provided to medical facilities in the country starting in December 2021....It is expected that an injectable form of the drug will also be included in the recommendations, as it is more effective for treating hospitalized patients. The final decision will be made by the Ministry of Health of the Russian Federation on the next revision of the interim guidelines on the prevention, diagnosis and treatment of new Covid-19 infections."

Non-US regulatory • Infectious Disease • Novel Coronavirus Disease